Isolated Noncompaction of the Ventricular Myocardium
Conditions
Keywords
Isolated Noncompaction of the Ventricular Myocardium, Prognostic factors
Brief summary
This study intends to retrospectively-prospectively enroll NVM patients from multiple centers to establish a natural population cohort of NVM patients. By collecting clinical data and biological samples from surgical patients, the investigators will construct a prognosis prediction system for NVM, optimize risk stratification, explore new strategies for the early prevention and treatment of NVM, and improve the efficiency of clinical treatment of NVM patients.
Detailed description
This study intends to retrospectively-prospectively enroll NVM patients from multiple centers to establish a natural population cohort of NVM patients. By collecting clinical data and biological samples from surgical patients, the investigators will construct a prognosis prediction system for NVM, optimize risk stratification, explore new strategies for the early prevention and treatment of NVM, and improve the efficiency of clinical treatment of NVM patients.
Interventions
BIOLOGICALDiagnosis of NVM
The term 'left ventricular non-compaction' (LVNC) has been used to describe a ventricular phenotype characterized by prominent LV trabeculae and deep intertrabecular recesses. The myocardial wall is often thickened with a thin,compacted epicardial layer and a thickened myocardial layer. In some patients, this abnormal trabecular architecture is associated with LV dilatation and systolic dysfunction. Left ventricular non-compaction is frequently a familial trait and is associated with variants in a range of genes, including those encoding proteins of the sarcomere, Z-disc, cytoskeleton, and nuclear envelope.
Sponsors
First Affiliated Hospital Xi'an Jiaotong University
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* The diagnosis of nvm was confirmed by cardiac ultrasound, electrocardiogram, magnetic resonance angiography, pathological examination and gene sequencing. * Patients or their families agreed to participate in the study and authorized informed consent.
Exclusion criteria
* Incomplete clinical data. * Do not agree to the inclusion or refuse to authorize the informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in the incidence of mortality rate | At diagnosis, before discharge (about 7 days), 1, 3, 6, 9 month, 1, 2, 3 year. | The survival status will be obtained from the medical records and phone calls to patients or their family members. |
Countries
China
Contacts
Primary ContactYang Yan
Backup ContactGuoliang Li
Outcome results
None listed